Channel Therapeutics CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Pelthos Therapeutics Inc. filed its Q2 2026 Form 10-Q, detailing a substantial net loss, a material weakness in financial reporting, and updates on its product portfolio and financing.
Pelthos Therapeutics Inc. has filed an amendment to its Q1 2026 report to restate financial statements due to errors in convertible debt valuation, revealing a material weakness in internal controls.
Pelthos Therapeutics Inc. reported a net loss of $10.2 million for the first quarter of 2026, with revenues driven by its lead product, ZELSUVMI.
Pelthos Therapeutics Inc. reported its Q3 2025 financial results, marking its first product revenues following the commercial launch of ZELSUVMI, alongside significant merger and financing activities, but also disclosed substantial net losses and material weaknesses in internal controls.
Pelthos Therapeutics reports increased losses but secures $50.1 million in new capital and completes a transformative merger, shifting focus to commercializing FDA-approved Zelsuvmi.
10-Q: Channel Therapeutics Reports Q1 2025 Results, Citing Going Concern Uncertainty Amidst Merger Plans
Channel Therapeutics reports a net loss of $1.97 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also announcing a merger agreement with LNHC, Inc.
10-Q: Chromocell Therapeutics Reports Q3 2024 Results, Cites Ongoing Development of Pain Therapeutics
Chromocell Therapeutics reported a net loss of $6.0 million for the nine months ended September 30, 2024, while continuing to advance its pain treatment programs.
Chromocell Therapeutics reported a net loss of $4.3 million for the second quarter of 2024, alongside updates on its clinical programs and financial position.
Chromocell Therapeutics reported a net loss of $2.56 million for the first quarter of 2024, following its initial public offering in February.